Journal: Molecular Oncology

Article Title: Focal adhesion kinase inhibitors are potent anti‐angiogenic agents

doi: 10.1016/j.molonc.2011.10.004

Figure Lengend Snippet: FAK inhibitors decrease number of viable endothelial cells in a dose‐dependent manner. HUVEC were incubated with various concentrations of either PF‐228 (A) or FI14 (B) in the presence of VEGF. Cells treated with vehicle (DMSO) were used ...

Article Snippet: Recombinant human vascular endothelial growth factor (VEGF) (rhVEGF 165 ; R&D Systems, Minneapolis, MN) was reconstituted according to the manufacturer's instructions.

Techniques: Incubation

Journal: Molecular Oncology

Article Title: Focal adhesion kinase inhibitors are potent anti‐angiogenic agents

doi: 10.1016/j.molonc.2011.10.004

Figure Lengend Snippet: FAK inhibitors induce cell cycle arrest and apoptosis in treated endothelial cells. Seeded HUVEC were treated with DMSO as vehicle control or varying concentrations of PF‐228 or FI14 in the presence of 50 ng/mL VEGF for 48 h. ...

Article Snippet: Recombinant human vascular endothelial growth factor (VEGF) (rhVEGF 165 ; R&D Systems, Minneapolis, MN) was reconstituted according to the manufacturer's instructions.

Techniques: Control

Journal: Molecular Oncology

Article Title: Focal adhesion kinase inhibitors are potent anti‐angiogenic agents

doi: 10.1016/j.molonc.2011.10.004

Figure Lengend Snippet: FAK inhibitors block HUVEC sprouting on collagen I gels. For assessing formation of sprouts, HUVEC were seeded onto collagen I gel‐coated plates and treated with 50 ng/ml VEGF in the absence (with added DMSO as a vehicle control) ...

Article Snippet: Recombinant human vascular endothelial growth factor (VEGF) (rhVEGF 165 ; R&D Systems, Minneapolis, MN) was reconstituted according to the manufacturer's instructions.

Techniques: Blocking Assay, Control

Journal: Translational Vision Science & Technology

Article Title: Sema3A Antibody BI-X Prevents Cell Permeability and Cytoskeletal Collapse in HRMECs and Increases Tip Cell Density in Mouse Oxygen-Induced Retinopathy

doi: 10.1167/tvst.11.6.17

Figure Lengend Snippet: Diagrammatic representation of sprouting angiogenesis in the retina, adapted from Sapieha. Initially, tip cell filopodia are stimulated by proangiogenic factors, such as VEGF-A. Via a combination of pericyte detachment from the vascular basement membrane, matrix metalloproteinase-induced degradation of the basement membrane, and loosening of VE–cadherin junctions, tip cell filopodia migrate through the basement membrane and search for vascular guidance cues. Chemoattractive cues include VEGF-A, whereas chemorepulsive cues include Sema3A. , Subsequently, endothelial cells adjacent to the tip cells (i.e., “stalk” cells) proliferate in response to proangiogenic factors (e.g., VEGF-A) to elongate the neovessels. – Sema3A, semaphorin 3A; VE, vascular endothelial; VEGF-A, vascular endothelial growth factor-A.

Article Snippet: The HRMECs were treated overnight with either 100 ng/mL recombinant human (rh) VEGF-A (293-VE010; R&D Systems, Inc., Minneapolis, MN, USA) or 500 ng/mL rh-Sema3A (1250-S3; R&D Systems) with and without 1 µg/mL of BI-X or 1 µg/mL of anti-trinitrophenol (TNP; 1B7.11 [ATCC TIB-191]; American Type Culture Collection, Manassas, VA, USA).

Techniques: Membrane

Journal: Translational Vision Science & Technology

Article Title: Sema3A Antibody BI-X Prevents Cell Permeability and Cytoskeletal Collapse in HRMECs and Increases Tip Cell Density in Mouse Oxygen-Induced Retinopathy

doi: 10.1167/tvst.11.6.17

Figure Lengend Snippet: Effects of BI-X, Sema3A, and VEGF-A on HRMEC permeability in vitro. Data are presented as mean ± SEM (group size, eight wells/group) and represent one of two independent experiments with comparable results. Statistical analysis was performed by one-way analysis of variance with Dunnett's post hoc multiple comparisons test versus Sema3A (*** P < 0.001). HRMEC, human retinal microvascular endothelial cell; SEM, standard error of the mean; Sema3A, semaphorin 3A; TNP, trinitrophenol; VEGF-A, vascular endothelial growth factor-A.

Article Snippet: The HRMECs were treated overnight with either 100 ng/mL recombinant human (rh) VEGF-A (293-VE010; R&D Systems, Inc., Minneapolis, MN, USA) or 500 ng/mL rh-Sema3A (1250-S3; R&D Systems) with and without 1 µg/mL of BI-X or 1 µg/mL of anti-trinitrophenol (TNP; 1B7.11 [ATCC TIB-191]; American Type Culture Collection, Manassas, VA, USA).

Techniques: Permeability, In Vitro